Real-World Study of Sacituzumab Govitecan for Breast Cancer
Part of Cancer clinical trials.
This study looks at how well the drug Sacituzumab Govitecan works in real-life settings for people with certain types of advanced breast cancer that have not responded to prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a type of breast cancer called triple-negative or HR+/HER2- that has spread or cannot be removed by surgery
- You have had at least two previous systemic treatments, with at least one for advanced disease (for HR+/HER2- type, you also need prior endocrine therapy)
- You are currently receiving or about to receive Sacituzumab Govitecan as your next treatment
- You are willing to use effective birth control if you or your partner could become pregnant
- You do not have serious infections, other cancers within the last 5 years, or major organ failure
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a drug called sacituzumab govitecan works and how safe it is for people with a certain type of breast cancer that has spread (HER2-negative metastatic breast cancer). It aims to understand real-world results for patients in China.
This trial tests a new drug, Sacituzumab Govitecan, for people with advanced triple-negative breast cancer that hasn't been treated yet. The goal is to see if it can shrink tumors or slow the cancer's growth.
This trial tests whether a drug called sacituzumab govitecan can help prevent a low white blood cell count (neutropenia) in people with metastatic triple-negative breast cancer. It is for patients who have already received some chemotherapy but need a new treatment option.
This trial studies how well sacituzumab govitecan (a targeted cancer drug) works for metastatic breast cancer that is HER2-negative. The study focuses on real-world patient experiences and quality of life in Chinese patients.
This study is tracking how people with metastatic triple-negative breast cancer feel and function during treatment with sacituzumab govitecan or other chemotherapy. It aims to understand real-world benefits from the patient's perspective.
This study is testing a drug called sacituzumab govitecan (SG) for people with advanced triple-negative breast cancer who have already had other treatments. The goal is to see how well the drug works and what side effects it causes, using your tumor samples to look for clues (biomarkers).
Hear when a new Treatment Outcome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.